Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

US: AIPLA urges Federal Circuit not to proscribe patents for biomedical diagnostic tools: Prometheus v Mayo (Inventive Step) (Hal Wegner) (Patently-O) (Holman’s Biotech IP Blog)

Lovenox (Enoxaparin) – US: Aventis files for certiorari: challenging Federal Circuit’s low standard for intent to deceive in inequitable conduct proceedings: Aventis Pharma v Amphastar Pharmaceuticals and Teva (Patently-O)

Ellen ‘t Hoen leaves Medecins Sans Frontieres Access to Essential Medicines campaign to become senior advisor on IP at UNITAID (Managing Intellectual Property)

New international pharma industry leader brings prospect of change (Intellectual Property Watch)

Competition authorities could be least of big Pharma’s worries (IAM)

Hope for consensus on WHO and counterfeits moves to May assembly (Intellectual Property Watch)

WHO global strategy on IP and health considered, implementation advances (Intellectual Property Watch)

SPCs and paediatric market exclusivity (The SPC Blog)

Nature Biotechnology – Survey finds scientists believe IP protection has negative effect on biological research (Michael Geist) (Ars Technica)

EU: European Commission attacks practices that prevent competition from generic drugs (Philip Brooks’ Patent Infringement Updates)

France: French SPC decisions (The SPC Blog) (The SPC Blog)

Inca Empire: Regional government of Cusco passes law on indigenous knowledge and biopiracy (TK Community)

Netherlands Patent Office decision: Zero term SPCs (The SPC Blog)

UK: Bioscience 2015 reviewed and refreshed (IP finance)

US: BIO CEO outlines challenges for Obama Administration (Patent Docs)

US: AIPLA urges Federal Circuit not to proscribe patents for biomedical diagnostic tools: Prometheus v Mayo (Inventive Step) (Hal Wegner) (Patently-O) (Holman’s Biotech IP Blog)

US: Classen v Biogen: Request for rehearing (Patently-O)

US: Caliper sues Shimadzu over DNA research patents (Law360)

US: Sequence listing e-filing options using EFS-Web (Patent Docs)

Actonel (Risedronic) – US: Procter & Gamble Co and Hoffman-La Roche file lawsuit against Sun Pharma over generic Actonel ANDA (Law360) (GenericsWeb)

Allegra (Fexofenadine) – US: Aventis files another patent suit, this time against Sun Pharmaceuticals, over Allegra (Law360)

Azopt (Brinzolamide) – US: Elan Pharma accuses Alcon Laboratories’ Azopt of infringing two patents (Law360)

Lexapro (Escitalopram) – US: Caraco files new declaratory action against Forest Laboratories over third patent for Lexapro (Law360)

Lovenox (Enoxaparin) – US: Aventis files for certiorari: challenging Federal Circuit’s low standard for intent to deceive in inequitable conduct proceedings: Aventis Pharma v Amphastar Pharmaceuticals and Teva (Patently-O)

Skelaxin (Metaxalone) – US: E D New York nixes therapeutic pharma patent using Bilski: King Pharmaceuticals, Inc et al v EON Labs, Inc (Peter Zura’s 271 Patent Blog)

Suprane (Desflurane) – US: Baxter sues Minrad over plans to make generic Suprane (Law360) (GenericsWeb)